Popmenu Raises $65M Funding Round Led by Tiger Global to Accelerate A.I.-Powered Digital Solution for Restaurants
11 Jun, 2021
– Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
– New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.